GNRH1 and pachyonychia congenita: In a trial in patients with PC (> 70 years, or low bone mass with T-score < -1) undergoing surgical castration or ADT with GnRH agonists, a reduction in the risk of new vertebral fractures was observed after 12 months of denosumab treatment (compared to placebo).